Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - NSCLC, metastatic 1

1735 - Overall survival results of ceritinib in ALKi-naïve patients with ALK-rearranged NSCLC (ASCEND-3)


19 Oct 2018


Poster Discussion session - NSCLC, metastatic 1


Targeted Therapy

Tumour Site


Enriqueta Felip


E. Felip1, M. Nishio2, S. Orlov3, K. Park4, C. Yu5, C. Tsai6, M. Cobo7, M. McKeage8, W. Su9, T. Mok10, G.V. Scagliotti11, D. Spigel12, V.Q. Passos13, Z. Chen13, A.T. Shaw14

Author affiliations

  • 1 Oncology Service, Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, 08035 - Barcelona/ES
  • 2 Department Of Thoracic Medical Oncology, Japanese Foundation for Cancer Research, Tokyo/JP
  • 3 Oncology, Department of Thoracic Oncology, St. Petersburg State Medical University, St. Petersburg/RU
  • 4 Department Of Medicine, Division of Hematology & Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul/KR
  • 5 Department Of Internal Medicine, National Taiwan University, Taipei/TW
  • 6 Department Of Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei/TW
  • 7 Medical Oncology, Medical Oncology Section, Hospital Regional Universitario Carlos Haya, IBIMA, Málaga/ES
  • 8 School Of Medical Sciences, Auckland City Hospital and University of Auckland, Auckland/NZ
  • 9 Department Of Internal Medicine, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan/TW
  • 10 Clinical Oncology, Chinese University of Hong Kong, Shatin/CN
  • 11 Department Of Oncology, University of Torino, Department of Oncology, Orbassano, Torino/IT
  • 12 Department Of Oncology, Medical Oncology, Sarah Cannon Research Institute, Nashville, Tennessee/US
  • 13 Oncology, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey/US
  • 14 Mgh Cancer Center, Massachusetts General Hospital, Boston, Massachusetts/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1735


The previous analysis of phase 2, ASCEND-3 study (NCT01685138; data cutoff: November 15, 2015) demonstrated prolonged median progression-free survival (mPFS) with ceritinib 750 mg/d (fasted) in ALKi-naïve patients with ALK+ NSCLC, who had received ≤3 prior lines of chemotherapy. The current analysis (data cutoff: January 22, 2018) from ASCEND-3 study reports the final safety and efficacy results including overall survival (OS).


ASCEND-3 is a multicenter, single-arm, open-label, phase 2 study in ALKi-naïve patients (aged, ≥18 years) with locally advanced or metastatic ALK+ NSCLC, who had received ≤3 lines of chemotherapy. Patients received oral ceritinib 750 mg/d (fasted). Primary endpoint was overall response rate (ORR) per RECIST v1.1 (by investigator). Secondary endpoints were ORR (by blinded independent review committee [BIRC]); overall intracranial response rate (OIRR), duration of response (DOR), disease control rate (DCR), PFS (by investigator and BIRC); OS; and safety.


Of 124 ceritinib-treated patients, 123 (99.2%) had received prior antineoplastic regimens (31 patients [25.0%], ≥3 regimens), and 49 (39.5%) had baseline brain metastases. Median follow-up time was 52.14 months (range, 48.4-60.1). Median duration of drug exposure was 23.2 months (range, 0.1-55.2). Median OS was 51.3 months (95% CI: 42.7, 55.3). Other efficacy results are shown in the table below. The most common adverse events (AEs [all grades], ≥60% of patients), suspected to be drug related, were diarrhea (83.1%), nausea (76.6%), and vomiting (69.4%). Grade 3/4 AEs suspected to be drug related were reported in 81 patients (65.3%). Overall, 18 patients (14.5%) had an AE leading to treatment discontinuation.

Investigator Assessment

(N* = 124)

BIRC Assessment

(N* = 124)
Overall response rate, n (%) (95% CI) 84 (67.7) (58.8, 75.9) 79 (63.7) (54.6, 72.2)
Disease control rate, n (%) (95% CI) 112 (90.3) (83.7, 94.9) 107 (86.3) (79.0, 91.8)

Median duration of response (in responders), months (95% CI)

M = 84

24.0 (14.8, 37.5)

M = 79

27.3 (16.6, 44.3)
Median progression-free survival, months (95% CI) 16.6 (11.0, 23.2) 19.4 (10.9, 29.3)

*Total number of patients included in the full analysis set.

Total number of patients with confirmed complete response or partial response.


Ceritinib demonstrated prolonged and clinically meaningful OS, PFS, and DOR in chemotherapy pretreated (≤3 lines), ALKi-naïve patients with ALK+ NSCLC. The safety profile is consistent with the previous studies.

Clinical trial identification


Editorial Acknowledgement

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.